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Introduction: Estrogen receptor (ER) signaling and its interaction 
with epidermal growth factor receptor (EGFR) is a potential thera-
peutic target in non–small-cell lung cancer (NSCLC). To explore 
cross-communication between ER and EGFR, we have correlated ER 
pathway gene and protein expression profiles and examined effects 
of antiestrogens with or without EGFR inhibitors in preclinical mod-
els of human NSCLC.
Methods: We evaluated 54 NSCLC cell lines for growth inhibition 
with EGFR inhibitors, antiestrogen treatment, or the combination. 
Each line was evaluated for baseline ER pathway protein expres-
sion. The majority were also evaluated for baseline ER pathway gene 
expression. Human NSCLC xenografts were evaluated for effects of 
inhibition of each pathway, either individually, or in combination.
Results: The specific antiestrogen fulvestrant has modest single 
agent activity in vitro, but in many lines, fulvestrant adds to effects 
of EGFR inhibitors, including synergy in the EGFR-mutant, erlo-
tinib-resistant H1975 line. ERα, ERβ, progesterone receptor-A, 
progesterone receptor-B, and aromatase proteins are expressed in all 
lines to varying degrees, with trends toward lower aromatase in more 
sensitive cell lines. Sensitivity to fulvestrant correlates with greater 
baseline ERα gene expression. Tumor stability is achieved in human 
tumor xenografts with either fulvestrant or EGFR inhibitors, but 
tumors regress significantly when both pathways are inhibited.
Conclusions: These data provide a rationale for further investiga-
tion of the antitumor activity of combined therapy with antiestrogen 
and anti-EGFR agents in the clinic. Future work should also evaluate 
dual ER and EGFR inhibition in the setting of secondary resistance 
to EGFR inhibition.
Key Words: Epidermal growth factor receptor, Estrogen, Estrogen 
receptor, Lung cancer, Fulvestrant.
(J Thorac Oncol. 2013;8: 270-278)
Lung cancer is the leading cause of cancer death among both men and women in the United States.1 A great deal of work 
has focused on the role of epidermal growth factor receptor 
(EGFR) in non–small-cell lung cancer (NSCLC).2,3 Erlotinib 
is the only U.S. Food and Drug Administration–approved 
EGFR tyrosine kinase inhibitor (TKI), inducing objective 
tumor responses in approximately 10% of unselected NSCLC 
patients.4 Patient selection is clearly important, with great-
est benefit from erlotinib seen in patients whose tumors har-
bor EGFR mutations.2,3,5 Even in this population, responses 
are often quite transient and resistance eventually emerges. 
Although there are several different mechanisms by which 
EGFR-mutant NSCLC eventually become resistant to EGFR 
TKIs, resistance in approximately half of the cases is caused 
by a secondary mutation in exon 20 at position 790 (T790M).6
The estrogen receptor (ER) pathway is among the most 
well-studied pathways in breast cancer,7 but its role in NSCLC 
has only been explored more recently as lung cancer rates 
among women have increased in recent decades.8 New data 
from randomized, prospective clinical trials show a signifi-
cant impact of hormone replacement therapy (HRT) in lung 
cancer. In the Women’s Health Initiative, over 16,000 post-
menopausal women with an intact uterus and no breast cancer 
history were randomly allocated to supplemental estrogen and 
progesterone or no HRT. After 5.6 years of study and 2.4 years 
of follow-up, the hazard ratio for lung cancer incidence in the 
HRT group was 1.28 (p = 0.12), with hazard ratio for death in 
NSCLC patients and death specifically from NSCLC was 1.61 
(p = 0.02) and 1.87 (p = 0.004), respectively.9 Furthermore, a 
prospective cohort study confirmed an increased, dose-depen-
dent lung cancer risk among women who received HRT.10
Antiestrogens demonstrate impressive efficacy in breast 
cancer, when tumors express ERs with relatively modest 
toxicity.11 Accumulating evidence now supports a potential 
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stimulatory role for ER pathway in NSCLC pathogenesis and 
for ER inhibition in NSCLC suppression.12–17 Significant ER 
expression is seen in lung cancer tissue and cell lines, particularly 
adenocarcinoma.14,18 Estrogens stimulate proliferation in vitro 
and progression in vivo in lung cancer models.19 Data from 
mouse models show that inhibition of this pathway can reduce 
the development of lung cancer.20 In a retrospective analysis of 
a European database, a reduced risk of lung cancer death was 
seen in women with breast cancer, if they received antiestrogen 
therapy, tamoxifen in most cases.21 Molecular details of the 
interaction between ER and EGFR are emerging, and ER seems 
to be an important locus for signal convergence.22–24 Clinical 
evaluation to date includes a phase I study showing safety 
and potential antitumor activity of gefitinib and fulvestrant in 
postmenopausal women,25 and data demonstrating safety of 
erlotinib combined with fulvestrant.26–28
MATERIALS AND METHODS
Cell Lines, Cell Cultures and Reagents
Erlotinib and fulvestrant were studied in 54 NSCLC 
cell lines in vitro (A427, A549, Calu-1, Calu-3, Calu-6, 
H23, H226, H358, H441, H460, H520, H522, H596, H661, 
H810, H838, H1155, H1299, H1385, H1435, H1437, H1563, 
H1568, H1581, H1623, H1651, H1666, H1703, H1734, 
H1755, H1793, H1836, H1838, H1869, H1944, H1975, 
H2023, H2030, H2073, H2106, H2110, H2122, H2126, 
H2135, H2172, H2228, H2286, H2291, H2342, H2405, 
H2444, HCC827, SHP77, SK-LU-1). The breast cancer line 
MCF-7 was evaluated in additional analyses. All lines were 
obtained from American Type Culture Collection (ATCC) 
and identity was confirmed by genomic DNA, in comparison 
with the ATCC database, within 3 months of the described 
experiments.
A549 was cultured in HAM’s F12 (ATCC, Manassas, 
VA) supplemented with 5% heat-inactivated fetal bovine 
serum (FBS) and 1% penicillin G-streptomycin-fungizone 
solution (PSF, Irvine Scientific, Santa Ana, CA). Calu-3 and 
SK-LU-1 were grown in EMEM (ATCC) 10% FBS and 1% 
PSF. H1155, H1435, H1581, H2286, and H2405 were grown 
in ACL-4 10% FBS or PSF. H1836, H2342, and H810 were 
grown in HITES 10% FBS or PSF. Remaining cell lines were 
cultured in RPMI 1640 (Cellgro, Manassas, VA) 10% FBS or 
PSF and 2 mmol/l glutamine (Invitrogen, Carlsbad, CA). Each 
cell line was also grown in a second proliferation experiment 
using phenol red-free media with dextran-coated charcoal-
stripped (DCC) FBS (same concentration as above). F-12K 
and EMEM were replaced by RPMI for these experiments and 
estrogen was not added to HITES, but the type of media was 
otherwise unchanged.
HCC827 harbors an EGFR mutation in exon 19, and 
H1975 harbors both an L858R mutation and a T790M muta-
tion in EGFR. All other cell lines evaluated harbored wild-type 
EGFR genes. KRAS was mutant in the following lines: A427, 
A549, Calu-1, Calu-6, H23, H358, H441, H460, H1155, 
H1385, H1944, H2030, H2122, H2291, H2444, SHP77, and 
SK-LU-1 (sequenome data were unavailable for H1836). 
ATCC classifies the following cells as adenocarcinoma: Calu-
3, H23, H522, H838, H1437, H1563, H1568, H1651, H1734, 
H1755, H1793, H1838, H1944, H1975, H2030, H2122, 
H2228, H2291, H2342, H2405, SK-LU-1; bronchoalveolar: 
H358, H441, H1666; large cell: H460, H661, H810, H1155, 
H1299, H1581; adenosquamous: H596, H1703; squamous: 
H226 and H520. Calu-6 is classified as anaplastic, SHP77 is 
classified as neuroendocrine, and the other cell lines do not 
have a specific histology allocated.
Western Blots
Cells growing in log-phase were washed in ice-cold 
PBS and lysed at 4°C in lysis buffer. Insoluble material was 
cleared by centrifugation at 10,000 g for 10 minutes. Protein 
was quantitated using BCA (Pierce Biochemicals, Rockford, 
IL), resolved by sodium dodecyl sulfate polycrylamide gel 
electrophoresis, and transferred to nitrocellulose membranes 
(Invitrogen). Expression was detected by ERα (62A3) Ab: 
#2512 (Cell Signaling, Danvers, MA), ERβ Ab: #5513 (Cell 
Signaling), progesterone receptor (PR)-A and PR-B (6A1) 
Ab: #3172 (Cell Signaling), Aromatase Ab: Abcam #ab18995 
(Abcam, Cambridge, MA), and α-Tubulin antibody #2144 
(Cell Signaling).
Microarray Analysis of Cell Lines
Agilent microarray analysis was performed to assess base-
line gene expression as previously described.29 Baseline microar-
rays were performed on Agilent Human 1A V2 chips (Agilent 
Technologies, Inc., Santa Clara, CA) with individual cell lines 
(labeled with cyanine-5) characterized by comparison to a 
NSCLC cell line mixed reference pool29 (labeled with cyanine-3) 
on a single slide. Slides were read using an Agilent Scanner, and 
gene expression values were calculated using Agilent Feature 
Extraction software version 7.5. Extracted data were imported 
into Rosetta Resolver 5.1 (Rosetta Inpharmatics, Agilent 
Technologies, Palo Alto, CA) to create expression profiles. Heat 
maps evaluated cell lines across probes corresponding to genes 
for ERα, ERβ, PR, and aromatase.
Proliferation Assays
For experiments looking at erlotinib and fulvestrant 
individually, cells were seeded in duplicate at 5000 to 10,000 
cells per well. The day after plating, drug was added with a 
starting concentration of 10 μM with twofold dilutions over 
12 concentrations. Cells were harvested by trypsinization 
and counted immediately using a Coulter Z2 particle counter 
(Beckman Coulter Inc., Brea, CA). Cells were counted on 
the day drug was added and 5 days later with percent growth 
inhibition defined as 100 × (1 − [generations in treated wells/
generations in untreated controls]). Concentration leading to 
50% inhibition (IC
50
) was calculated using a four-parameter 
logistic model. For synergy assays, the process was the same 
with both drugs added at a 1:1 ratio at a starting concentration 
of 10 μM with twofold dilutions over six concentrations. 
Combination index was calculated based on method C 
as described elsewhere (Calcusyn; Biosoft, Cambridge, 
Cambridgeshire, UK).30 For surveying the entire panel with 
both drugs, in duplicate experiments, fulvestrant was added 
with a starting concentration of 10 μM with twofold dilutions 
over six concentrations in the presence of erlotinib 1 μM.
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Apoptosis Analysis
Effects of erlotinib, fulvestrant, and the combination on 
apoptosis were assessed in duplicate experiments using Nim-
4′,6-diamidino-2-phenylindole staining. Cells were plated 
evenly in control and experimental wells and allowed to grow 
to log-phase, then treated with 1 μM erlotinib, 200 nM fulves-
trant or the combination for 72 hours. Cells were washed with 
PBS, and trypsin was applied, and then centrifuged at 775 g for 5 
minutes. Supernatant was aspirated and cells were resuspended 
in 100 μl of Nim-4′,6-diamidino-2-phenylindole (NPE Systems, 
Pembroke Pines, FL) and gently vortexed. Cells were analyzed 
with UV using a Cell Lab Quanta SC flow cytometer (Beckman 
Coulter Inc.).
In Vivo Analysis of EGFR TKIs Plus Fulvestrant
A549 cells (5 × 107 cells/mouse) were injected subcu-
taneously (SQ) in ovariectomized nude mice with estradiol-
17β supplements in a biodegradable binder (1.7 mg/pellet; 
Innovative Research, Peary Court Novi, MI) as before.31 When 
tumors reached 50 to 75 mm3, mice were randomized to treat-
ment groups of six to eight mice and administered vehicle 
control, gefitinib (160 mg/kg daily), fulvestrant 5 mg SQ 
weekly, or a combination of gefitinib and fulvestrant at the 
doses above, for 21 days. The experiment was continued to 
day 28. An independent experiment used an identical design, 
but erlotinib (25 mg/kg by oral gavage daily for 21 days), 
replaced gefitinib, and the experiment was continued until 
tumors achieved a limiting volume of 500 mm3 as before.32 
Data are presented as mean ± SEM for tumor volumes mea-
sured in mm3. Tumor volumes of mice in the single treatment 
and combination treatment arms were compared with con-
trols, and to each other. Data were analyzed using analysis of 
variance and Student’s t tests.
RESULTS
Sensitivity to Erlotinib and Fulvestrant 
Differs Among Human NSCLC Cell Lines
Significant differences were found in the antiproliferative 
effects of erlotinib across the cell lines in our panel, with IC
50
 
of less than 1 μM in six lines, including the extremely sensi-
tive EGFR-mutant line HCC827, a line with a known deletion 
in exon 19 of the EGFR gene (Fig. 1A). Seven lines had IC
50
 
less than 5 μM for fulvestrant in standard media (Fig. 1B), and 
eight had IC
50
 less than 5 μM in phenol red-free media with 
DCC-FBS with a trend toward greater sensitivity across the 
cell panel in this estrogen-depleted media (Fig. 1C). The breast 
cancer cell line MCF-7 was used as a positive control, and in 
phenol red-free media with DCC-FBS, the IC
50
 was below the 
lowest dose (325 nM) tested (data not shown). To assess com-
bined effects of fulvestrant with erlotinib, sensitivity to fulves-
trant in the setting of 1 μM erlotinib was evaluated across the 
cell line panel. Assessing the panel at 2.5 μM of fulvestrant 
plus 1 μM erlotinib demonstrated several lines in which ful-
vestrant added significantly to the inhibition seen with erlotinib 
alone. This was shown particularly in lines with greater sensi-
tivity to fulvestrant as a single agent (Fig. 1D). The changes 
with lower doses of fulvestrant showed similar results with 
slightly less inhibition (Supplemental Figure, Supplemental 
Digital Content 1, http://links.lww.com/JTO/A378).
Western Blot and Microarray Evaluation of 
NSCLC Cell Lines Identify Potential Biomarkers 
for Efficacy of ER Inhibition in NSCLC
To assess baseline levels of relevant pathway genes 
and proteins, the cell line panel was evaluated by microarray 
analysis, using a hormonal gene set and Western blots for 
ERα, ERβ, aromatase, PR-A, and PR-B when compared with 
a tubulin control. No clear association was seen between sen-
sitivity to fulvestrant and protein levels of ERα, ERβ, PR-A, 
or PR-B; however, there was a trend toward lower aromatase 
levels in cell lines with greater sensitivity to fulvestrant (Fig. 
2A, B). Baseline gene expression data were available for 44 
of the 54 lines. Microarray analysis demonstrated low vari-
ability across the panel in comparison to a similar analysis 
in our group’s breast cancer panel.33 There was a greater sen-
sitivity in cell lines with higher ESR1 gene expression, the 
gene for ERα. One group of cell lines, including 20 of the 
44 lines for which we had baseline expression data, were 
defined by elevated ESR1 expression. This group included 
all four lines with IC
50
 lesser than 5 μM (p < 0.022), using 
standard media and four of 5 lines with IC
50
 less than 5 μM 
(p < 0.1) in phenol red-free media with DCC-FBS (Fig. 2C).
In Vivo Evaluation of the Combination of  
Inhibition of EGFR and ER Pathways 
Demonstrates Significant and Sustained  
Tumor Inhibition
Mice harboring tumors from human NSCLC A549 line 
were randomly assigned to vehicle control, gefitinib 160 mg/
kg daily, fulvestrant 5 mg SQ weekly, or gefitinib plus ful-
vestrant for a total of 21 days. Gefitinib alone delayed tumor 
growth, whereas fulvestrant alone led to tumor stabilization. 
Treatment with both gefitinib and fulvestrant elicited signifi-
cantly reduced tumor volume when compared with all other 
treatments (p < 0.001), with no visible tumors after sev-
eral weeks of therapy (Fig. 3A). When a similar study was 
conducted with erlotinib as the EGFR TKI, as previously 
reported,31 tumor volumes of mice in the combination arm 
(fulvestrant and erlotinib) were significantly different from all 
other treatments (p < 0.001). We have now followed animals 
treated on the combination arm for 60 days, and tumor recur-
rence was not seen over that time (Fig. 3B).
Combination of Erlotinib and Fulvestrant Is 
More Effective than Either Agent Alone in a 
Model Harboring a Secondary EGFR Mutation
To assess whether antiestrogen therapy can overcome 
secondary EGFR TKI resistance, dose-response curves for the 
combination of erlotinib and fulvestrant were generated for the 
H1975 line. This line is resistant to EGFR TKIs and harbors two 
mutations in the EGFR gene, the sensitizing L858R mutation 
and the T790M mutation which is associated with EGFR TKIs 
resistance. In this model, the combination of erlotinib and 
fulvestrant demonstrated synergy (Fig. 4A). When evaluating 
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FIGURE 1.  In vitro sensitivity to 
erlotinib, fulvestrant, and the com-
bination of both agents—54 NSCLC 
cell lines with IC50 for (A) erlotinib 
and (B) fulvestrant using ATCC-
recommended media are presented 
in μM. C, IC50 values for fulvestrant 
in lines grown in phenol red-free 
media with DCC-FBS are shown. D, In 
phenol red-free media with DCC-FBS, 
sensitivity to combined erlotinib 1 
μM and fulvestrant 2.5 μM is shown, 
with fulvestrant (white bars), erlotinib 
(gray bars), and the combination 
(black bars). Lines are arranged in 
descending order of the difference in 
IC50 between combination treatment 
and erlotinib, with boxes around 
cell lines with IC50 for fulvestrant of 
less than 5 μM. Error bars indicate 
standard error based on duplicate 
experiments. NSCLC, non–small-cell 
lung cancer; ATCC, American Type 
Culture Collection; IC50, concentra-
tion leading to 50% inhibition; FBS, 
fetal bovine serum; DCC, dextran-
coated charcoal-filtered.
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FIGURE 2.  Baseline expression of hormone recep-
tor genes and proteins. A and B, For each cell line, 
protein levels of ERα, ERβ, PR-A, PR-B, aromatase, and 
tubulin were evaluated by established Western blot 
methods. Green bars by the cell line name indicate 
an IC50 of less than 5 μM in the ATCC-recommended 
media, whereas red bars by the cell line name 
indicate an IC50 of less than 5 μM in phenol red-free 
media with DCC-FBS. C, In a subset of evaluated cell 
lines, baseline gene expression data were available, 
and expression of a hormonal gene set is shown 
with an X marking lines with an IC50 of less than 5 
μM. ATCC, American Type Culture Collection; DCC, 
dextran-coated charcoal-filtered; FBS, fetal bovine 
serum; PR, progesterone receptor; IC50, concentration 
leading to 50% inhibition.
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apoptosis in the H1975 cell line, low doses of fulvestrant 
(200 nM) led to increased apoptosis at 72 hours compared with 
control. A slight increase in apoptosis at 72 hours was seen in 
response to erlotinib 1 μM, but the combination of erlotinib and 
fulvestrant led to a large increase in apoptosis (Fig. 4B).
DISCUSSION
The role of ER signaling in NSCLC is an emerging area 
of interest based on laboratory discoveries and clinical data. 
We demonstrate that components of the hormone receptor 
FIGURE 3.  In vivo evaluation of gefitinib, fulvestrant, and 
the combination of both drugs in human A549 xenografts 
in nude mice. A, Ovariectomized nude mice with estradiol 
supplements and A549 tumors received 21 days of vehicle 
control (squares), gefitinib (circles) 160 mg daily, fulves-
trant (triangles) 5 mg SQ weekly, or the combination of 
gefitinib and fulvestrant (diamonds). B, The same model 
was assessed with erlotinib (circles) as the EGFR TKI. Mice 
were treated with assigned therapy for 21 days, and then 
followed for 60 days to assess outcomes. EGFR TKI, epider-
mal growth receptor factor tyrosine kinase inhibitors; SQ, 
subcutaneously.
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FIGURE 4.  In vitro effects of erlotinib, fulvestrant, or the 
combination of both agents on EGFR TKI-resistant, EGFR-
mutant lung cancer cell proliferation and viability. Growth 
curves of the H1975 line after 6 days of treatment with erlo-
tinib (diamonds), fulvestrant (squares), or the combination 
of the two drugs (triangles) are shown at the concentrations 
listed. A, Combination index for the combination at constant 
ratio. B, Apoptosis at 72 hours was assessed in H1975 cells 
with no therapy (white), erlotinib 1 μM (stripes), fulvestrant 
200 nM (black), or the combination (checked). Error bars 
indicate standard error based on duplicate experiments. 
EGFR TKI, epidermal growth receptor factor tyrosine kinase 
inhibitors.
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signaling pathway (including ERα, ERβ, PR-A, PR-B, and 
aromatase) are present ubiquitously, but to varying degrees, 
throughout a large panel of human NSCLC cell lines. To our 
knowledge, this is the most comprehensive evaluation to date 
of human NSCLC cell lines for gene and protein expression in 
this signaling pathway.
Fulvestrant was selected for use in these studies because 
it is generally regarded as a pure antiestrogen that selectively 
inhibits ER signaling in target cells.34,35 Furthermore, fulves-
trant was shown to exhibit significant antitumor activity in 
NSCLC cells in vitro and in vivo, and the drug showed evi-
dence of significant interactions with EGFR TKIs.14,31 In the 
present studies, single agent antitumor activity with fulves-
trant in vitro was modest, but was observed more frequently 
in NSCLC lines with increased ESR1 gene expression. The 
results achieved statistical significance for cells maintained 
in standard media and a trend in phenol red-free media with 
DCC-FBS. We note that the higher frequency of drug inhibi-
tory activity was not directly related to the level of ESR1 RNA, 
but instead correlated with the ESR1 high group. This finding 
is considered hypothesis-generating. These data contrast with 
some data suggesting that ERβ is more relevant in NSCLC, 
but the relative contribution of different components of this 
pathway remains an area of active investigation.16 Patients 
with higher levels of estrogenic stimulus would be a group 
for whom there is a great clinical need, as a review of survival 
by estrogen levels among several Southwest Oncology Group 
trials showed lower survival in women with higher estrogen 
levels.36 Similarly, Olivo-Marston et al.37 report a significant 
association of increased serum estrogen levels with poorer 
survival among male and female lung cancer patients. In addi-
tion, our findings show a trend toward increased fulvestrant 
sensitivity in lines with lower levels of aromatase protein as 
reported by others,16 although this trend is difficult to quan-
titate and cannot be considered definitive data on its own. 
Estrogen levels in lines with lower aromatase levels should be 
lower, thus allowing fulvestrant to compete with less endog-
enous estrogens for ER binding.
For proliferation assays, two sets of experiments were 
conducted. Cells were grown in either ATCC-recommended 
media or in phenol red-free media with DCC-FBS with a 
trend toward greater sensitivity in the latter analysis. As a 
potential screening tool, we also evaluated the entire panel for 
sensitivity to fulvestrant in the presence of 1 μM of erlotinib. 
Although dose-response curves were generated across the 
panel, it was more representative to graph percent inhibition at 
a single point across the cell line panel. The combination data 
correlated well with sensitivity to erlotinib, but in cell lines in 
which the dual therapy significantly surpassed the response 
to erlotinib alone, the sensitivity to fulvestrant was generally 
high, as was the level of ESR1 gene expression. Of note, there 
are some lines for which the dual treatment seemed to have 
antagonistic effects. There is some clinical precedence for such 
an effect, in which the addition of an EGFR TKI elicits worse 
outcomes.38 Further characterization of individual patients that 
may potentially experience harm will be important as clinical 
evaluation of this combination treatment regimen proceeds. 
It is possible that, in some subsets of NSCLC, erlotinib is not 
an appropriate partner for antiestrogen therapy. However, as 
reported previously in breast cancer, the synergy seen in some 
lung cancer cell lines with dual antiestrogen and EGFR or 
epidermal growth factor receptor kinase inhibitors could well 
be attributable to biological interactions between estrogen and 
EGFR signaling pathways.35,39 Indeed, significant molecular 
interactions of estrogen and EGFR signaling pathways in 
NSCLC cells have now been reported in several independent 
investigations.14,16,21,23,24
In an attempt to correlate sensitivity with protein lev-
els of ER pathway genes, we evaluated the entire panel by 
Western blot. For each protein, we selected a single antibody. 
The antibodies used have not been clinically validated, and in 
the context of the ongoing clinical trial, we will use clinically 
validated antibodies. We also evaluated most of the cell lines 
(all of the lines for which we have baseline gene expression 
data) for ER pathway genes, using the Agilent platform which 
compares a sample to a reference, namely pooled NSCLC cell 
lines. By definition, there will be cell lines with lower and 
higher expression than the pooled average, but the magni-
tude of differences was narrow when compared with a similar 
breast cancer panel in our laboratory. The evaluation of cell 
lines against a control of pooled cell lines could be another fac-
tor responsible for differences between our observations and 
those of others with respect to the relative importance of ERα 
and ERβ. Our analysis does not assess differences between 
normal tissues and cancerous tissue, but instead assesses dif-
ferences among different cancer models. This approach is 
designed to identify subgroups within a given histology in 
which disproportionate benefit would be expected.40,41
In patients managed with EGFR inhibitors, drug 
resistance eventually occurs. Of patients with EGFR mutations 
(e.g., exon 19 deletions or the L858R mutation in exon 
21), significant initial response to erlotinib is observed, but 
approximately half develop T790M mutations at the time of 
tumor progression. The H1975 cell line was chosen for further 
investigation based on molecular characteristics consistent 
with this clinical scenario. In the H1975 cell line, which has a 
T790M mutation, dual treatment with erlotinib and fulvestrant 
in vitro leads to significantly greater inhibition and induction 
of apoptosis than either agent given alone. The mechanism of 
this increased sensitivity to EGFR inhibition after the addition 
of an antiestrogen is not clear. Recent work by Xu et al.42 
demonstrates that estrogen can increase phospho-EGFR and 
that this effect can be inhibited by gefitinb or fulvestrant, but 
it is inhibited to a greater degree when both agents are used. 
We are planning further experiments to elucidate potential 
molecular mechanisms responsible for this effect. Such work 
will include evaluation of antiestrogens in the setting of cell 
lines that are initially sensitive to EGFR TKIs, but develop 
acquired resistance after exposure to erlotinib, rather than the 
de novo resistant H1975 cell lines.
In a NSCLC cell line for which neither erlotinib nor ful-
vestrant had appreciable single agent in vitro activity in these 
experiments, namely A549 cells, the combination of EGFR 
inhibition and ER inhibition led to significant tumor resolution 
in an in vivo setting. These results are striking and were not 
predicted by in vitro drug sensitivity or baseline expression 
levels of ER pathway protein or gene expression. The selec-
tion of the A549 cell line for in vivo work was made on the 
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basis of data showing expression and activity of ERs among 
initially surveyed NSCLC cell lines.15 It is notable that H23 
lung tumor cells also demonstrate significant additive antitu-
mor effects in vivo when fulvestrant is combined with a differ-
ent EGFR kinase inhibitor,43 despite an antagonistic effect in 
vitro. The fact that synergy between antiestrogens and EGFR 
kinase inhibitors is significant in vivo but less significant in 
lung tumor cells used during in vitro assays of synergy poses 
interesting questions to be addressed more fully in future 
work. For example, in this study, we explored alternative in 
vitro assay conditions (e.g., with or without steroid-depleted 
culture medium) to find if the in vitro assay may be less sensi-
tive than the in vivo system because of competition for ful-
vestrant binding to tumor cell ER. As shown in the results, 
this may have been a small factor influencing antiestrogen 
activity. Another factor may be that the tumor microenviron-
ment and neighboring cells (absent in the in vitro assay) may 
play a role in modulating either estrogen or EGFR signaling. 
In studies on the action of antiestrogens in preventing lung 
carcinogenesis in vivo, Stabile et al.17 similarly report that the 
tumor niche may have an important effect on the in vivo activ-
ity of antiestrogens. Finally, some actions of estrogens in lung 
in vivo may be because of interaction with subpopulations 
of tumor progenitor cells or stimulation of tumor-associated 
angiogenesis,44 actions that may be better assessed using in 
vivo models of tumor progression. One or more of these fac-
tors may explain differences observed between in vitro and in 
vivo assays of estrogen and EGFR signaling.
In addition to independent evidence on significant inter-
actions of estrogen and EGFR signaling in NSCLC,20,45 results 
described in this article helped to develop and launch an ongo-
ing, randomized phase II clinical trial of dual erlotinib and 
fulvestrant therapy when compared with erlotinib alone in 
previously treated NSCLC patients. All patients participating 
in the clinical trial were required to provide a tissue sample, 
and we plan to analyze these specimens for EGFR mutation 
status and expression of ER and aromatase, with a focus on 
identification of biomarkers that may identify an optimal 
patient population for further development of antiestrogen 
therapy in NSCLC.
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